Cargando…

Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors

BACKGROUND: Neuroendocrine tumors (NETs) overexpress somatostatin receptors (SSTRs). METHODS: We developed a second-generation, ligand-based, anti-SSTR chimeric antigen receptor (CAR) incorporating the somatostatin analog octreotide in its extracellular moiety. RESULTS: Anti-SSTR CAR T cells exerted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mandriani, Barbara, Pellè, Eleonora, Mannavola, Francesco, Palazzo, Antonio, Marsano, Renè Massimiliano, Ingravallo, Giuseppe, Cazzato, Gerardo, Ramello, Maria Cecilia, Porta, Camillo, Strosberg, Jonathan, Abate-Daga, Daniel, Cives, Mauro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240886/ https://www.ncbi.nlm.nih.gov/pubmed/35764366 http://dx.doi.org/10.1136/jitc-2022-004854

Ejemplares similares

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy
por: Lee, Lydia, et al.
Publicado: (2023)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
por: Bachiller, Mireia, et al.
Publicado: (2021)

Automated, scaled, transposon-based production of CAR T cells
por: Lock, Dominik, et al.
Publicado: (2022)

CD47 expression is critical for CAR T-cell survival in vivo
por: Beckett, Alex N, et al.
Publicado: (2023)

Large-scale manufacturing and characterization of CMV-CD19CAR T cells
por: Wang, Xiuli, et al.
Publicado: (2022)

Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
por: Martín-Otal, Celia, et al.
Publicado: (2022)

Serpin B9 controls tumor cell killing by CAR T cells
por: Kimman, Thomas, et al.
Publicado: (2023)

Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19(+) malignancy
por: Pennell, Christopher A, et al.
Publicado: (2022)

Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor
por: Zhang, Boning, et al.
Publicado: (2020)

First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G
por: Anna, François, et al.
Publicado: (2021)

Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
por: Huckaby, Justin T, et al.
Publicado: (2021)

CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies
por: Abdin, Shifaa M., et al.
Publicado: (2021)

Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
por: Sun, Ming, et al.
Publicado: (2023)

CAR T-cell detection scoping review: an essential biomarker in critical need of standardization
por: Turicek, David P, et al.
Publicado: (2023)

Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia
por: Wen, Jingjing, et al.
Publicado: (2023)

Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts
por: Quintarelli, Concetta, et al.
Publicado: (2021)

CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity
por: Jess, Jennifer, et al.
Publicado: (2023)

Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells
por: Fang, Karen Kai-Lin, et al.
Publicado: (2023)

Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma
por: McKenna, Mary K, et al.
Publicado: (2023)

Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma
por: Sun, Luan, et al.
Publicado: (2021)

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

Deletion of Cbl-b inhibits CD8(+) T-cell exhaustion and promotes CAR T-cell function
por: Kumar, Jitendra, et al.
Publicado: (2021)

Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression
por: Mueller, Katherine P, et al.
Publicado: (2022)

Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
por: Schoutrop, Esther, et al.
Publicado: (2023)

Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model
por: Ranoa, Diana Rose E, et al.
Publicado: (2023)

Fully human antibody V(H) domains to generate mono and bispecific CAR to target solid tumors
por: Wang, Guanmeng, et al.
Publicado: (2021)

VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding
por: Lanitis, Evripidis, et al.
Publicado: (2021)

Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells
por: Kuo, Yi-Chiu, et al.
Publicado: (2022)

Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
por: Camviel, Nicolas, et al.
Publicado: (2022)

Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse
por: Liu, Lunan, et al.
Publicado: (2022)

Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering
por: Michels, Kathryn R, et al.
Publicado: (2023)

Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies
por: Temple, William C, et al.
Publicado: (2023)

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy
por: Zhang, Zhen, et al.
Publicado: (2020)

Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
por: Han, Lu, et al.
Publicado: (2020)

Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study
por: Walti, Carla S, et al.
Publicado: (2021)

Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells
por: Tokatlian, Talar, et al.
Publicado: (2022)

Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
por: Christodoulou, Ilias, et al.
Publicado: (2021)

PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
por: Bajor, Malgorzata, et al.
Publicado: (2022)

Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy
por: Johnson, P Connor, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sl3hp59tqs2dl401ujdgm3qvc3